Jin Rong Jie·2025-08-14 04:40Core Viewpoint - Hualan Biological Vaccine Co., Ltd. has received implied approval for clinical trials of its "Lyophilized Haemophilus influenzae type b Conjugate Vaccine" aimed at preventing invasive diseases caused by Haemophilus influenzae type b [1] Company Overview - Hualan Biological Vaccine Co., Ltd. was established in 2005 and is located in Xinxiang City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 601.0275 million RMB and a paid-in capital of 360 million RMB [1] - Hualan Biological has made investments in 2 companies and participated in 980 bidding projects, holding 41 patents and 138 administrative licenses [1] Shareholder Information - Major shareholders include Hualan Biological Engineering Co., Ltd. with a 75% stake, Kecang Co., Ltd. with 10%, Henan Huaying Enterprise Management Consulting Partnership (Limited Partnership) with 9%, and Xinxiang Chenyi Qiming Management Consulting Partnership (Limited Partnership) with 6% [1]